Another benefit to tumor cells from S100B-dependent inhibition of IL6 secretion could be to prevent IL6 activation of B cells, T lymphocytes, and dendritic cells as a means to avoid an anti-tumor immune response at an early stage or in regions with little or no signs of a stress-response. The gene discussed is IL6; the disease is neoplasm.